Pharmacopeia
GABAPENTIN
Core pharmacology
- Chemical Pharmaceutics
acetic acid derivate - structural analogue of GABA
- Volume of distribution
0.85 L/kg
- Introduction
acetic acid derivative which is a structural analogue of
GABA.- Onset Peak Duration
Peak plasma levels within 2-3hrs
- Special Points
- enchances morphine effect - removed by haemodialysis - BA dec with increasing dose - Antacids decrease BA
- Indications Uses
1. post-herpetic neuralgia 2. painful diabetic neuropathy 3. partial seizures with or without secondary generalization, and 4. neuropathic pain
- Presentation
600/800 mg tablets and 100/300/400 mg capsules
- Mechanism of action
structurally related to GABA but does not interact with GABA receptors. The binding site for the drug is the alpha-2-delta subunit of voltage-gated calcium channels. Gabapentin does not interact with sodium channels in vitro (cf. phenytoin, carbamazepine). It may also: 1. partially reduce the response to the glutamate agonist NMDA 2. reduce the release of monoamine neurotransmitters in vitro 3. stimulate glutamate decarboxylase (the enzyme which converts glutamate to GABA), and 4. increase the synaptic release of GABA
- Physiological effects
CNS Gabapentin has analgesic and anticonvulsant properties and improves sleep in patients with neuropathic pain.
- Adverse Effects Toxicity
Dizziness, ataxia, nystagmus, somnolence, tremor, diplopia, nausea, and vomiting occur with a frequency >5%. Leucopenia, erectile dysfunction, and weight gain
- Protein binding
Not protein bound
- Half-life
T1/2: 5-7 hrs Clearance proportional to creatinine clearance
- Route And Dose
PO only 900-3600mg/day in 3 divided doses Dose reduced in renal failure Discontinuation at least over a week
- Absorption
Well absorbed after oral administration; bioavailability about 60%.
- Distribution
Vd about 0.85 l/kg.
- Metabolism
Not significantly metabolised.
- Excretion
Predominantly renal excretion, largely unchanged.
- Class Group
Anticonvulsant and non-opioid analgesic used for neuropathic pain.